Barusiban - Ferring Pharmaceuticals

Drug Profile

Barusiban - Ferring Pharmaceuticals

Alternative Names: FE 200 440

Latest Information Update: 15 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Oligopeptides; Tocolytics
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Female infertility
  • Discontinued Preterm labour

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 15 Jan 2018 Barusiban is still at phase II development stage for Female infertility in Australia, Belgium, Canada, Czech Republic, Poland and Spain (SC)
  • 15 Jan 2018 Discontinued - Phase-II for Preterm labour (Prevention) in Finland, Lithuania, Poland, Romania, Czech Republic, Belgium (IV) (Indication not listed on Ferring pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top